Abbott Laboratories

NYSE:ABT

Medical - Devices

Healthcare
$104.48 -0.58%

-$0.51 today

Market cap
$180.95B
Beta
0.62
P/E (TTM)
24.5
EPS (TTM)
$3.59
Dividend yield
2.77%
52W Low $81.97High $139.06

Volume 7.02M

Average 13.17M

ABT EBITDA Margin

EBITDA as a percentage of revenue.

Abbott LaboratoriesNYSE: ABT

EBITDA Margin · Q3 FY2026 · quarter ended Sep 2026

EBITDA Margin narrows to 11.3%

EBITDA Margin was 11.3% in Q3 FY2026, down 15.9 pp from a year earlier. On a trailing-twelve-month basis it was 20.1%, down 6.8 pp year over year. Over 3 fiscal years it narrowed by 0.3 pp.

Context

  • EBITDA Margin widened in 1 of the last 3 fiscal years.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 20 analysts of 29.3% for the fiscal year ending Dec 2026, up from 26.9% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
11.3%-10.9 pp QoQ
Last fiscal yearDec 2025
26.9%+1.1 pp YoY
LTMSep 2026
20.1%-6.8 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-15.9 pp+8.4 pp+24.3 pp
1 year+1.1 pp+2.4 pp+1.4 pp
3 years-0.3 pp+2.0 pp+2.3 pp
5 years+2.8 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
26.9%
Year-over-year change
+1.1pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How ABT compares with its peers on the latest reported figures

  • ABT's LTM Sep 2026 EBITDA Margin of 20.1% is the 9th highest of the 10 companies compared; the peer median is 25.9%.
  • Its year-over-year change of -6.8 pp is the 8th highest of 10, against a peer median of -0.6 pp.
  • Over three fiscal years its change of -0.3 pp compares with a peer median of +1.0 pp.
ABT Competitors Peer median
EBITDA Margin for ABT and competitors
Company Period LTM level YoY 3-year change
JNJJohnson & JohnsonLTM Sep 202631.0% -11.9 pp+10.3 pp
DHRDanaher CorporationLTM Sep 202627.7% -0.6 pp-7.3 pp
BSXBoston Scientific CorporationLTM Jun 202627.6% +2.2 pp+3.8 pp
MDTMedtronic plcLTM Jul 202627.3% +0.0 pp-0.9 pp
SYKStryker CorporationLTM Jun 202625.9% +5.9 pp+3.4 pp
EWEdwards Lifesciences CorporationLTM Jun 202624.3% -7.1 pp-12.4 pp
TMOThermo Fisher Scientific Inc.LTM Sep 202623.7% -2.2 pp-0.9 pp
BDXBecton, Dickinson and CompanyLTM Sep 202623.4% +1.3 pp+1.0 pp
ABTAbbott LaboratoriesLTM Sep 202620.1% -6.8 pp-0.3 pp
GEHCGE HealthCare Technologies Inc.LTM Jun 202615.2% -4.0 pp+1.1 pp
Peer median (excluding ABT) 25.9%-0.6 pp+1.0 pp

Competitors are the stored peer set for ABT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue43.08B43.65B40.11B41.95B44.33B
Cost of Revenue19.86B21.33B20.07B20.63B19.72B
Gross Profit23.21B22.32B20.04B21.33B24.61B
Gross Margin53.9%51.1%50.0%50.8%55.5%
Research & Development2.74B2.85B2.72B2.82B2.96B
Selling, General & Admin11.28B11.11B10.88B11.65B12.38B
Operating Expenses14.01B13.96B13.6B14.47B16.59B
Depreciation & Amortization3.54B3.27B3.24B3.22B3.12B
EBITDA12.16B11.89B10.61B10.83B11.92B
EBITDA Margin28.2%27.2%26.4%25.8%26.9%
Operating Income9.2B8.36B6.44B6.83B8.05B
Operating Margin21.4%19.2%16.0%16.3%18.2%
Interest Income43M183M385M344M230M
Interest Expense410M315M698M603M341M
Other Income / Expenses(989M)(56M)229M188M418M
Income Before Tax8.21B8.31B6.66B7.01B8.47B
Pre-Tax Margin19.1%19.0%16.6%16.7%19.1%
Income Tax Expense1.14B1.37B941M(6.39B)1.94B
Net Income7.07B6.93B5.72B13.4B6.52B
Net Margin16.4%15.9%14.3%31.9%14.7%
EPS (Basic)3.973.943.307.673.74
EPS (Diluted)3.943.913.277.643.72
Weighted Avg Shares1.78B1.75B1.73B1.73B1.75B
Weighted Avg Shares (Diluted)1.79B1.76B1.75B1.75B1.75B

Abbott Laboratories

NYSE:ABT

Intrinsic Alpha fair value

Locked

Current Price

$104.48

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.